About Us > Our results

Our Results

Our net sales revenue was EUR 510 million in the 2016/2017 financial year (lasting from 1 October to 30 September). 77% of our revenue derived from export in our key export markets: EUR 324 million in Russia and other CIS-countries and in Central and Eastern Europe. In our domestic market, Hungary Egis Pharmaceuticals PLC has traditionally been one of the market leaders. Our company ranks first on the basis of the number of packages sold in the Hungarian market. In accordance with our strategic goals we launched 10 new product lines in our markets in the 2016/2017 financial year. At the end of the financial year we had 414 domestic registrations and 2997 abroad.

Three therapeutic areas are in the focus of our R&D activities: the cardiovascular, the central nervous and the respiratory systems, which altogether account for two-thirds of our sales revenue. Although we continue to place the main emphasis on these areas, we continuously open towards new therapeutic areas.


The most important key to our competitiveness and our future success is innovation, to which we dedicate an outstanding amount every year. In the 2016/2017 financial year we spent EUR 42 million on research and development.

Our performance is the joint achievement of more than 4300 colleagues working in Hungary and at our affiliates and subsidiaries in various parts of the world.